Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $19 to $17.
July 25, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Sage Therapeutics but lowers the price target from $19 to $17.
The maintained Sector Outperform rating is positive, but the lowered price target may indicate some concerns about future performance, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100